XML 31 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Segment Reporting
 6 Months Ended
Jun. 30, 2024
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
We operate in, and report financial information for, the following two segments: Medical Office and Life Science Portfolio and SHOP. We aggregate the operating results of our properties in these two reporting segments based on their similar operating and economic characteristics. Our Medical Office and Life Science Portfolio segment primarily consists of medical office properties leased to medical providers and other medical related businesses, as well as life science properties primarily leased to biotech laboratories and other similar tenants. Our SHOP segment consists of managed senior living communities that provide short term and long term residential living and, in some instances, care and other services for residents where we pay fees to managers to operate the communities on our behalf.
We also report “non-segment” operations, which consists of triple net leased senior living communities and wellness centers that are leased to third party operators from which we receive rents, which we do not consider to be sufficiently material to constitute a separate reporting segment, and any other income or expenses that are not attributable to a specific reporting segment.
For the Three Months Ended June 30, 2024
 Medical Office and Life Science PortfolioSHOPNon-SegmentConsolidated
Revenues:    
Rental income$54,555 $— $8,315 $62,870 
Residents fees and services— 308,522 — 308,522 
Total revenues54,555 308,522 8,315 371,392 
Expenses:    
Property operating expenses24,282 279,538 245 304,065 
Depreciation and amortization18,975 46,911 2,471 68,357 
General and administrative— — 6,262 6,262 
Acquisition and certain other transaction related costs
— — 1,826 1,826 
Impairment of assets6,545 — — 6,545 
Total expenses49,802 326,449 10,804 387,055 
Loss on sale of properties(13,213)— — (13,213)
Interest and other income— — 2,403 2,403 
Interest expense(894)(61)(57,747)(58,702)
Loss on modification or early extinguishment of debt— — (209)(209)
Loss before income tax expense and equity in net (losses) earnings of investees(9,354)(17,988)(58,042)(85,384)
Income tax expense— — (170)(170)
Equity in net (losses) earnings of investees(21,493)— 9,186 (12,307)
Net loss$(30,847)$(17,988)$(49,026)$(97,861)
 For the Six Months Ended June 30, 2024
 Medical Office and Life Science PortfolioSHOPNon-SegmentConsolidated
Revenues:    
Rental income$108,704 $— $16,816 $125,520 
Residents fees and services— 616,648 — 616,648 
Total revenues108,704 616,648 16,816 742,168 
Expenses:    
Property operating expenses48,179 562,954 536 611,669 
Depreciation and amortization39,715 93,833 4,942 138,490 
General and administrative— — 13,830 13,830 
Acquisition and certain other transaction related costs
— — 1,912 1,912 
Impairment of assets18,687 — — 18,687 
Total expenses106,581 656,787 21,220 784,588 
Loss on sale of properties(19,087)— — (19,087)
Interest and other income— — 4,640 4,640 
Interest expense(1,116)(129)(115,033)(116,278)
Loss on modification or early extinguishment of debt— — (209)(209)
Loss before income tax expense and equity in net (losses) earnings of investees(18,080)(40,268)(115,006)(173,354)
Income tax expense— — (357)(357)
Equity in net (losses) earnings of investees(19,880)— 9,471 (10,409)
Net loss$(37,960)$(40,268)$(105,892)$(184,120)
 As of June 30, 2024
 Medical Office and Life Science PortfolioSHOP Non-SegmentConsolidated
Total assets$1,778,781 $3,103,090 $451,576 $5,333,447 
 For the Three Months Ended June 30, 2023
 Medical Office and Life Science PortfolioSHOPNon-SegmentConsolidated
Revenues:    
Rental income$53,368 $— $8,005 $61,373 
Residents fees and services— 284,846 — 284,846 
Total revenues53,368 284,846 8,005 346,219 
Expenses:    
Property operating expenses23,938 261,959 331 286,228 
Depreciation and amortization22,855 43,152 2,387 68,394 
General and administrative— — 7,284 7,284 
Acquisition and certain other transaction related costs
— — 6,043 6,043 
Impairment of assets11,299 — — 11,299 
Total expenses58,092 305,111 16,045 379,248 
Interest and other income— 1,466 3,668 5,134 
Interest expense(116)(152)(47,116)(47,384)
Loss before income tax expense and equity in net earnings of investees(4,840)(18,951)(51,488)(75,279)
Income tax expense— — (221)(221)
Equity in net earnings of investees2,929 — — 2,929 
Net loss$(1,911)$(18,951)$(51,709)$(72,571)
 For the Six Months Ended June 30, 2023
 Medical Office and Life Science PortfolioSHOP Non-SegmentConsolidated
Revenues:    
Rental income$110,390 $— $17,421 $127,811 
Residents fees and services— 564,438 — 564,438 
Total revenues110,390 564,438 17,421 692,249 
Expenses:    
Property operating expenses47,453 524,288 567 572,308 
Depreciation and amortization42,890 85,304 5,000 133,194 
General and administrative— — 13,157 13,157 
Acquisition and certain other transaction related costs
— — 6,136 6,136 
Impairment of assets13,607 3,617 — 17,224 
Total expenses103,950 613,209 24,860 742,019 
Gain on sale of properties— 1,233 — 1,233 
Gains on equity securities, net— — 8,126 8,126 
Interest and other income— 1,466 7,863 9,329 
Interest expense(225)(423)(94,516)(95,164)
Loss on modification or early extinguishment of debt— — (1,075)(1,075)
Income (loss) before income tax expense and equity in net earnings of investees6,215 (46,495)(87,041)(127,321)
Income tax expense— — (190)(190)
Equity in net earnings of investees2,282 — — 2,282 
Net income (loss)$8,497 $(46,495)$(87,231)$(125,229)
 As of December 31, 2023
Medical Office and Life Science PortfolioSHOP Non-SegmentConsolidated
Total assets$1,866,422 $3,134,978 $444,736 $5,446,136